

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for manufacturing an inhalable medicament or part of an inhalable medicament for the treatment or prevention of pain in humans or animals, comprising: combining O<sub>2</sub> and gaseous nitrogen protoxide (N<sub>2</sub>O) ~~[[to]]~~ with at least one active product selected from the group consisting of paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine, and morphine mimetics.

2. (previously presented) The method according to claim 1, wherein the active product is chosen from among analgesics.

3. (previously presented) The method according to claim 1, wherein the active product is chosen from among compounds with an anti-inflammatory action.

4. (previously presented) The method according to claim 1, wherein the active product is chosen from among antipyretics.

5. (currently amended) The method according to claim 1, wherein said inhalable medicament further comprises a second gas selected from the group consisting of helium, ~~oxygen,~~ nitrogen,

xenon, hydrogen, carbon monoxide (CO), carbon dioxide (CO<sub>2</sub>), argon, krypton, nitrogen monoxide (NO), carbonated hydrocarbons, fluorocarbons, and mixtures of several of said second gases.

6. (previously presented) The method according to claim 1, wherein said inhalable medicament is in the form of an aerosol comprising said gas and said active product in the form of a powder, liquid or a powder/liquid mixture.

7. (previously presented) The method according to claim 1, wherein the inhalable medicament contains a therapeutically effective quantity of active product.

8. (previously presented) The method according to claim 1, wherein the combination of said at least one gas with said at least one active product leads to a synergistic effect.

9-10. (cancelled)

11. (previously presented) The method according to claim 1, wherein said inhalable medicament contains O<sub>2</sub> and N<sub>2</sub>O, and at least one active product with an analgesic action.

12. (currently amended) An inhalable medicament ~~formed by a combination of~~ comprising O<sub>2</sub> and gaseous nitrogen protoxide (N<sub>2</sub>O) ~~and in combination with~~ at least one active product with an analgesic action, said active product being selected from the group consisting of paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine, and morphine mimetics.

13. (currently amended) The medicament according to claim 12, said medicament further comprises a second gas selected from the group consisting of helium, ~~oxygen~~, nitrogen, xenon, hydrogen, carbon monoxide (CO), carbon dioxide (CO<sub>2</sub>), argon, krypton, nitrogen monoxide (NO), carbonated hydrocarbons, fluorocarbons, and mixtures of several of these gases.

14. (previously presented) The medicament according to claim 12, wherein said medicament contains a therapeutically effective amount of active product.

15. (cancelled)

16. (currently amended) A method for the treatment or prevention of pain in humans or in animals, comprising the step of administering an effective amount of an inhalable medicament or part of an inhalable medicament via the inhalation route said human or animal in need of treatment thereof, wherein said inhalable medicament or part of an inhalable medicament comprises O<sub>2</sub> and gaseous nitrogen protoxide (N<sub>2</sub>O) in combination with at least one active product selected from the group consisting of paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine, and morphine mimetics.

17. (previously presented) The method according to claim 16, wherein said active product is chosen from analgesics.

18. (previously presented) The method according to claim 16, wherein said active product is selected from compounds with an anti-inflammatory action.

19. (previously presented) The method according to claim 16, wherein said active product is selected from antipyretics.